ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1579840
This article is part of the Research TopicPrecision Oncology in Checkpoint Immunotherapy: Leveraging Predictive Biomarkers for Personalized TreatmentView all 23 articles
The germinal center-tertiary lymphoid structure (GC-TLS) after neoadjuvant chemo-immunotherapy for locally advanced lung squamous cell carcinoma can predict the disease progression
Provisionally accepted- 1Department of Pathology, West China Hospital, Sichuan University, Chengdu, China
- 2Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The tertiary lymphoid structures (TLSs) are the anti-tumor immune hubs in the tumor microenvironment. The germinal center (GC) (a marker of maturation) and spatial distribution of TLS may determine the responsiveness of immunotherapy. However, the regulatory mechanism of neoadjuvant chemotherapy (NACT) and combined immunotherapy (NACT-IO) on the dynamic remodeling of TLS has not been elucidated. Methods: The NACT-IO group (72 patients), NACT group (50 patients), UT group (50 patients, un-neoadjuvant therapy) were included. Multiple immunofluorescence (mIF) was used to analyze the difference of microenvironment in paired samples (the same case) pre and post neoadjuvant therapy. To further analyze the effect of treatment on the maturity and spatial distribution pattern of TLS (within/outside tumor bed) in postoperative samples, and to establish a quantitative method of TLS based on hot spot area to evaluate its prognostic value. Results: Spatial heterogeneity analysis that the density of total TLSs (t-TLSs) and GC-positive TLSs (GC-TLSs) in the tumor bed of NACT (p<0.01, p<0.01) group and NACT-IO (p<0.001, p<0.001) group were significantly higher than that outside the tumor bed. Compared with the UT group, NACT and NACT-IO significantly increased the density of t-TLSs (p<0.01, p<0.001) and GC-TLSs (p<0.01, p<0.01) in the tumor bed. In addition, there was an inverted U-shaped correlation between GC-TLS and treatment cycle: the density of GC-TLSs reaches the peak value after receiving two or less (≤ 2) cycles of NACT and NACT-IO, and decreased significantly after receiving more than two (> 2) cycles of NACT and NACT-IO (p<0.05). Multivariate Cox regression model confirmed that low GC-TLS burden (≤2/20×HPF) within tumor bed hotspots (HR=3.99, 95%CI=1.10-14.5, p=0.036) was superior to the traditional prognostic factor of pathological remission in ≤ 2-cycles of NACT-IO subgroup (HR=3.44, 95%CI=1.03-11.47, p=0.044), and became the strongest independent factor for predicting disease free survival (DFS). Conclusions: This study reveals for the first time that NACT and NACT-IO enhance anti-tumor efficacy through multidimensional (abundance, spatial distribution and maturity) dynamic remodeling of TLS, and proposes the short course of ≤ 2 cycles of NACT-IO can maximize the prognostic value of GC-TLS, providing key evidence for optimizing the treatment ' time window '.
Keywords: neoadjuvant chemoimmunotherapy, Lung squamous cell carcinoma, Prognostic biomarkers, Tertiary lymphoid structures (TLSs), Neoadjuvant chemotherapy
Received: 19 Feb 2025; Accepted: 21 Aug 2025.
Copyright: © 2025 Jiang, Shuang, zhou, Huang, Chen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lili Jiang, Department of Pathology, West China Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.